

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number  
**WO 2003/039553 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/565**,  
31/568, 31/137, A61P 15/02, 15/12, A61K 9/00 // (A61K  
31/568, 31:565, 31:137)

NJ 07930 (US). **VERSI**, Ebrahim [US/US]; 11 Sheethill  
Drive, Gladstone, NJ 07934 (US).

(21) International Application Number:  
PCT/US2002/036167

(74) Agent: **FORBES, James, C.**; Pharmacia Corporation,  
P.O. Box 5110, Chicago, IL 60680 (US).

(22) International Filing Date:  
12 November 2002 (12.11.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/344,507 9 November 2001 (09.11.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PHAR-**  
**MACIA CORPORATION** [US/US]; Corporate Patent  
Dept., 800 N. Lindbergh Boulevard, O4E, St. Louis, MO  
63167 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BILKEY, Chris, R.**  
[AU/AU]; 59 Kirby Street, Rydalmere, 2116 (AU). **SLAT-**  
**TER, Greg, J.** [US/US]; 18 Chesterbrook Road, Chester,

Published:

— with international search report

[Continued on next page]

(54) Title: COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION



(57) Abstract: A set of pharmaceutical dosage forms is provided, each comprising at least two therapeutic agents selected from (a) an estrogen, (b) an androgen, and (c) an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of female sexual dysfunction (FSD) or postmenopausal sexual avoidance (PMSA), said dosage forms being adapted for intravaginal administration. A method of treatment of FSD or PMSA comprises administering intravaginally, in a treatment regimen extending over a period of at least 7 days, dosage forms at least a portion of which comprise two or more therapeutic agents selected from (a) an estrogen, (b) an androgen, and (c) an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of FSD or PMSA, wherein no more than one dosage form is administered on any day. Also provided is a kit useful in implementing such a treatment regimen.

WO 2003/039553 A1

WO 2003/039553 A1



— with amended claims

**Date of publication of the amended claims:**

8 July 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**AMENDED CLAIMS**

[received by the International Bureau on 23 May 2003 (23.05.03)  
claims 1-24 substituted by claims 1-17]

**WHAT IS CLAIMED IS:**

1. A pharmaceutical dosage form comprising an estrogen and an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of female sexual dysfunction or disorders contributing thereto, said dosage form  
5 being adapted for intravaginal administration.
2. The dosage form of Claim 1 wherein said total and relative dosage amounts are therapeutically effective in treatment of female sexual dysfunction characterized at least by atrophic vaginitis and anxiety arising from urinary incontinence.
3. The dosage form of Claim 1 that is a vaginal dosage form selected from the  
10 group consisting of tablets, ovules, pessaries, creams, ointments, gels, foams, sponges and implants.
4. The dosage form of Claim 1 that is a vaginal tablet.
5. The dosage form of Claim 1 wherein the estrogen is a nonsteroidal estrogen selected from the group consisting of broparacetro, chlorotrianisone, dienestrol,  
15 diethylstilbestrol, fosfestrol, hexestrol, medhestrol and salts and esters thereof.
6. The dosage form of Claim 1 wherein the estrogen is a steroidal estrogen selected from the group consisting of colpormon, conjugated estrogenic hormones, equilenin, equilin, estradiol, estriol, estrone, ethinyl estradiol, mestranol, moxestrol, quinestradiol, quinestrol and salts and esters thereof.
- 20 7. The dosage form of Claim 1 wherein the estrogen is estradiol.
8. The dosage form of Claim 1 wherein the antimuscarinic is selected from the group consisting of oxybutynin, tolterodine, the 5-hydroxymethyl metabolite of tolterodine and salts and esters thereof.
9. The dosage form of Claim 1 wherein the antimuscarinic is tolterodine or a  
25 pharmaceutically acceptable salt thereof.
10. A pharmaceutical dosage form comprising an estrogen and an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of postmenopausal sexual avoidance, said dosage form being adapted for intravaginal administration.
- 30 11. The dosage form of Claim 10 that is a vaginal dosage form selected from the

group consisting of tablets, ovules, pessaries, creams, ointments, gels, foams, sponges and implants.

12. The dosage form of Claim 10 that is a vaginal tablet.
13. The dosage form of Claim 10 wherein the estrogen is a nonsteroidal estrogen  
5 selected from the group consisting of broparoestrol, chlorotrianisime, dienestrol, diethylstilbestrol, fosfestrol, hexestrol, methestrol and salts and esters thereof.
14. The dosage form of Claim 10 wherein the estrogen is a steroidal estrogen  
selected from the group consisting of colpormon, conjugated estrogenic  
hormones, equilenin, equilin, estradiol, estriol, estrone, ethinyl estradiol,  
10 mestranol, moxestrol, quinestradiol, quinestrol and salts and esters thereof.
15. The dosage form of Claim 10 wherein the estrogen is estradiol.
16. The dosage form of Claim 10 wherein the antimuscarinic is selected from the  
group consisting of oxybutynin, tolterodine, the 5-hydroxymethyl metabolite of  
tolterodine and salts and esters thereof.
- 15 17. The dosage form of Claim 10 wherein the antimuscarinic is tolterodine or a  
pharmaceutically acceptable salt thereof.